It is commonly used in research due to its stability and prolonged activity
doi: 10.1016/j.amjcard.2022.10.010
Combination with Insulin with or without Metformin In a 26-week double blind trial (Trial 6, NCT03021187), 731 adult patients with type 2 diabetes mellitus inadequately controlled on insulin (basal, basal/bolus or premixed) with or without metformin, were randomized to RYBELSUS 3 mg, 7 mg and 14 mg once daily or placebo once daily
Results confirmed that DRS remained significantly associated with overall survival even after adjusting for other clinical variables, including WHO grade, age at diagnosis, radiotherapy status, chemotherapy status, and 1p/19q codeletion status
[89] Kayshild is the first GLP-1 medicine approved for this indication
There is also the brand-equity question